- Trials with a EudraCT protocol (6)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
6 result(s) found for: CyTOF.
Displaying page 1 of 1.
EudraCT Number: 2018-001678-10 | Sponsor Protocol Number: NL65853.029.18 | Start Date*: 2019-06-06 |
Sponsor Name:VU Medical Center | ||
Full Title: Tofacitinib: salvage therapy for patients with RCDII - a pilot study | ||
Medical condition: Refractory celiac disease type II | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001853-15 | Sponsor Protocol Number: NL61830 | Start Date*: 2018-07-11 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: An explorative study for halting inflammation in patients with emphysema by intravenous administration of autologous bone marrow derived mesenchymal stromal cells. | ||
Medical condition: Pulmonary emphysema | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000169-60 | Sponsor Protocol Number: CA209-755 | Start Date*: 2017-05-23 | |||||||||||
Sponsor Name:VU University Medical Center | |||||||||||||
Full Title: A phase 2 study of nivolumab combined with daratumumab with or without low dose cyclophosphamide in relapsed/refractory multiple myeloma | |||||||||||||
Medical condition: relapsed/refractory multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003862-10 | Sponsor Protocol Number: Dara-Atra | Start Date*: 2016-04-01 | |||||||||||
Sponsor Name:VU University Medical Center | |||||||||||||
Full Title: A phase 1 and phase 2 study of daratumumab in combination with all-trans retinoic acid in relapsed/refractory multiple myeloma | |||||||||||||
Medical condition: relapsed/refractory multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004106-34 | Sponsor Protocol Number: Dastop2October17th2016 | Start Date*: 2017-03-06 |
Sponsor Name:Uppsala University Hospital | ||
Full Title: PERSISTENCE OF MAJOR MOLECULAR REMISSION IN CHRONIC MYELOID LEUKEMIA AFTER a second stop of TKI TREATMENT in patients who failed an initial stop attempt: A prospective multicenter study . | ||
Medical condition: Chronic Myeloid Leukemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) DK (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003335-29 | Sponsor Protocol Number: SIOPEATRT01 | Start Date*: 2021-04-15 |
Sponsor Name:German Pediatric Oncology Group, GPOH gGmbH | ||
Full Title: An international prospective umbrella trial for children with atypical teratoid/rhabdoid tumours (ATRT) including A randomized phase III study evaluating the non-inferiority of three courses of hig... | ||
Medical condition: atypical teratoid/rhabdoid tumours (ATRT) | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Ongoing) NO (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
